We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Cardiology

Journal Scan / Research · July 07, 2021

Design and Baseline Characteristics of the AMPLITUDE-O Cardiovascular Outcomes Trial of Efpeglenatide

Diabetes, Obesity & Metabolism

 

Additional Info

Disclosure statements are available on the authors' profiles:

Diabetes, Obesity & Metabolism
Design and Baseline Characteristics of the AMPLITUDE-O Cardiovascular Outcomes Trial of Efpeglenatide, a Weekly Glucagon-Like Peptide-1 Receptor Agonist
Diabetes Obes Metab 2021 Feb 01;23(2)318-323, HC Gerstein, K Branch, L Heenan, S Del Prato, NS Khurmi, CSP Lam, R Pratley, J Rosenstock, N Sattar

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading